title: Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families.
abstract: Approximately 70 families with familial isolated hyperparathyroidism (FIHP) have been reported. Whether it is a separate entity or a variant of multiple endocrine neoplasia type 1 (MEN1 at 11q13) or hyperparathyroidism-jaw tumor (HPT-JT or HRPT2 at 1q21-32) syndrome is not known. We describe here 3 unreported families with familial primary hyperparathyroidism and evaluate their clinical, pathological, and genetic profiles. Biochemical and radiological screenings for MEN1 were negative for all families. In 2 families with a total of 10 affected cases and 3 female obligate carriers, there is no evidence of jaw or renal lesions despite careful radiological investigations. In both families the disease was linked to the 1q21-q32 region with the maximum logarithm of the odds (lod) scores of 3.10 and 3.43 for markers D1S222 and D1S249 respectively, at recombination fraction of 0. In 1 family 2 types of parathyroid pathology were found: 3 of chief cell type and 1 of oxyphil/oncocytic cell type. Two chief cell tumors and 1 oxyphil tumor were found to have loss of heterozygosity (LOH) involving loss of the wild-type alleles for chromosome 1q markers. In the third family, with 4 affected siblings, a parathyroid carcinoma and 2 cases of polycystic kidney disease were found. The parathyroid carcinoma also showed loss of heterozygosity in the 1q region. In conclusion, we found that the hyperparathyroidism traits in a subset of FIHP families are linked to the 1q21-32 markers in the HRPT2 region. We describe the spectrum of parathyroid disease in 1q-linked families involving 3 different types of pathology and demonstrate for the first time loss of wild-type alleles in these parathyroid tumors. Taken together, the results suggest that some of the FIHP are a variant of HPT-JT and that the gene involved is a tumor suppressor gene.
authors.affiliation: Department of Molecular Medicine, Karolinska Hospital, Stockholm, Sweden. Bin.Teh@cmm.ki.se
authors.forename: B T
authors.initials: BT
authors.lastname: Teh
authors.forename: F
authors.initials: F
authors.lastname: Farnebo
authors.forename: S
authors.initials: S
authors.lastname: Twigg
authors.forename: A
authors.initials: A
authors.lastname: Höög
authors.forename: S
authors.initials: S
authors.lastname: Kytölä
authors.forename: E
authors.initials: E
authors.lastname: Korpi-Hyövälti
authors.forename: F K
authors.initials: FK
authors.lastname: Wong
authors.forename: J
authors.initials: J
authors.lastname: Nordenström
authors.forename: L
authors.initials: L
authors.lastname: Grimelius
authors.forename: K
authors.initials: K
authors.lastname: Sandelin
authors.forename: B
authors.initials: B
authors.lastname: Robinson
authors.forename: L O
authors.initials: LO
authors.lastname: Farnebo
authors.forename: C
authors.initials: C
authors.lastname: Larsson
mesh_terms: D000328:Adult; D000483:Alleles; D002874:Chromosome Mapping; D002878:Chromosomes, Human, Pair 1; D005260:Female; D006239:Haplotypes; D006801:Humans; D006961:Hyperparathyroidism / Q000235:genetics* / Q000473:pathology; D008126:Lod Score; D019656:Loss of Heterozygosity; D008297:Male; D010280:Parathyroid Glands / Q000473:pathology; D010282:Parathyroid Neoplasms / Q000235:genetics; D010375:Pedigree